Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Vorinostat for Relapsed/Refractory MLL-Rearranged Leukemias
NCT02419755Phase 2Terminated
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Apr 2015
- Primary completion
- Dec 2016
- Modality
- Modified Peptides, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, vorinostat in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL), sponsored by St. Jude Children's Research Hospital. Started Apr 2015; status: terminated.
02
Drugs
bortezomibvorinostat
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT02419755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02419755.